Vetren 30,000 gel, 100 g

Instructions for use for Vetren 30,000 gel, 100 g

Important notes (compulsory information):

Vetren gel 30,000 I.E. Active substance: heparin sodium. Applications: For supportive treatment in acute swelling states after dull traumas.

For risks and side effects, read the package leaflet and ask your doctor or pharmacist.


LEAFLET: INFORMATION FOR THE USER

Vetren Gel 30,000 I.E.
Active ingredient: heparin sodium
For use in adults.

Read the entire leaflet carefully because it contains important information for you. This medicine is available without prescription. In order to achieve the best possible treatment success, VETREN® Gel must be 30,000 I.e. However, to be applied correctly.

• Lift the package leaflet. You might want to read it again.
• Ask your pharmacist if you need more information or advice.
• If your symptoms get worse or no improvement occurs, you must definitely visit a doctor.
• If one of the listed side effects you significantly affect it or notice side effects that are not specified in this information information, please inform your doctor or pharmacist.

This leaflet contains:

1. What is Vetren® Gel 30.000 I.e. And what is it used for?
2. What you need before using VETREN® GEL 30,000 I.E. NOTE?
3. How is Vetren® Gel 30,000 I.e. Apply?
4. WHAT SIDE EFFECTS ARE POSSIBLE?
5. How is Vetren® Gel 30,000 I.e. Keeping?
6. ADDITIONAL INFORMATION

1.What is Vetren® Gel 30,000 I.E. And what is it used for?

Cloth or indicator group or mode of action:
Heparin for topical use to reduce swelling.

Application areas:
For supportive treatment in acute swelling states after blunt injury (bruises / bruises).

2.What, you need 30,000 I.E before using VETREN® Gel. NOTE?

VETREN® GEL 30,000 I.E. may not be used:

• if you are hypersensitive (allergic) against heparin or any of the other ingredients of VETEREN® GEL 30,000 I.e
• if you have an acute or prehistory of allergic waste of the number of platelets (thrombocytopenia type II) through heparin.

Take special care with VETREN® GEL 30,000 I.E. is required:
When creating new symptoms that can indicate a thrombosis or pulmonary embolism, such as

• Swelling and heat feeling in the affected part of the body,
• reddened and tense skin, possibly blue color,
• Voltage and pain in foot, calf and knee luck (Relieving at high bearing)
• suddenly air not, chest pain and weakness / collapse

the presence of a heparin-induced thrombocytopenia type II must be excluded and immediately the platelet count (Thrombocyte count) be controlled.

Regular controls of the thrombocyte values are required for each heparin application. Controls of the thrombocyte number should be made:

• before starting heparin gift
• on the 1th day after the beginning of the heparin gift
• then every 3-4 days to the end of heparin treatment

With simultaneous use of medicines that intervene in blood clotting, an increased risk of bleeding can not be excluded. Brueckers can occur more frequently or increase in expansion. During treatment with Vetren gel 30.000i.e. Are spraying in the muscle because of the risk of bruising (hematomas) to avoid. VETREN® GEL 30,000 I. E. should not be applied to open wounds and / or wetting eczema. VETREN® Gel 30.000 I.e. Is alcoholic and should therefore not come into contact with the eyes or mucous membrane.

When using VETREN® GEL 30,000 I.E. with other medicines:
Please inform your doctor or pharmacist if you take / use other medicines or recently taken / applied, even if it is non-prescription medicines. Interactions with other medicines are not known for local application, but can not be excluded in particular with prolonged application, since a penetration of heparin is described by the healthy skin. Especially in medicaments engaging in blood clotting, such as thrombocyte aggregation inhibitors (Acetylsalicylic acid, ticlopidine, clopidogrel, dipyridamol in high doses), fibrinolytika, other anticoagulants (cumarin derivatives), Non-steroidal anti-phlogistics (phenylbutazon, indometacin, sulfinpyrazon), glycoprotein-ILB / ILA receptor antagonists, penicillin in high doses, dextrane, can not be excluded increased risk of bleeding. Hematomas can be done or amplified.

Pregnancy and breast feeding period:
Previous experiences with the application for pregnant women and breastfeeders have not shown any indications of harmful effects. Heparin is not placato daytime and does not occur in breast milk.

Important information about certain other ingredients of VETREN® GEL 30.000i.e.:
Macrogolglycerolricinoleat (Ph. EUR.) Can cause skin irritation.

3.How is Vetren® Gel 30,000 I.e. Apply?

Use VETREN® GEL 30,000 I.E. Always follow the instruction in this leaflet. Please ask your doctor or pharmacist if you are not sure.

Unless otherwise prescribed by the doctor, the usual dose is:
VETREN® GEL 30,000 I. E. is to be applied 2-3 times daily thinly and evenly to the disease.

Duration of application:
VETREN® Gel 30.000 I.e. May not be used for more than 10 days.

If you have a larger amount of VETEREN® GEI 30,000 I.e. Applied than you should:
Please contact your doctor or a pharmacist if you have a larger amount of VETEREN® GEL 30,000 I.e. Applied than you should.

If you have forgotten the use of VETREN® GEL 30,000 I.E:
Do not apply twice the dose if you forget the previous application.

If you use the application of VETREN® GEL 30,000 I.E. Cancel:
If you want to interrupt the treatment or to quit prematurely, please consult with your doctor or pharmacist first.

4.What side effects are possible?

Like all medicines, VETREN® GEL can 30,000 I.e. Side effects that do not have to occur.

The frequency information on side effects is based on the following categories:
Very often:	more than 1 treated from 10
Frequently:	1 to 10 treated from 100
Occasionally:	1 to 10 treated from 1 000
Rarely:	1 to 10 treated from 10 000
Very rare:	less than 1 treated from 10 000
Not known:	Frequency on the basis of the available data does not estimate.

Possible side effects:
Allergic reactions to heparin when applying on the skin are very rare. However, in individual cases, allergic reactions such as redness of the skin and itching may occur, which usually disappear quickly after discontinuation of the preparation.

Blood and blood-forming system:
Unknown: The frequency of occurrence of heparin-induced, antibody-mediated platelet tie tops type II (reducing the number of platelets < 100 000 μl or a fast drop of the platelet count to < 50% of the output value), with arterial and venous thrombosis or embolism who can run deadly is at local application on the HaUT has not been studied so far. However, since the recording of heparin after local application has been described by the healthy skin, this risk can not be excluded with certainty. An increased attention is therefore indicated (see section 2). In patients without pre-existing hypersensitivity to heparin, the drop in the number of platelets usually begins 6-14 days after the start of treatment. In patients with hypersensitivity to heparin, this waste may occur within hours.

Please inform your doctor or pharmacist if one of the listed side effects will significantly affect it or notice side effects that are not specified in this document formation.

Which countermeasures are to take with side effects?
VETREN® GEL 30,000 I.E. Should be discontinued when allergic skin reactions occur. Please inform your doctor about this. In addition, no further special measures are necessary

5.How is Vetren® Gel 30,000 I.e. Storage?

Store drug out of reach of children.

Notes and information on the durability of the medicinal product:
You must not use the medicinal product according to the applicable on folding box and tube until - specified expiration date.

Note on durability after a break:
VETREN® GEL 30,000 I.E. is to be used after a break within 6 months.

6.Dearn information

What 100 g VETREN® GEL 30,000 I.E. contain:
The active ingredient is: heparin sodium 30,000 I.e.
The other ingredients are: Macrogolglycerolricinoleat (pH) EUR.); Load filth oil; Carbomer 940; Propane-2-ol; Sodium hydroxide; purified water.

Content of the pack:
Packs of 100 g gel

Pharmaceutic entrepreneur:
Rottapharm | Madaus GmbH
51101 Cologne
Tel.: 0221 / 8998-0
Fax: 0221 / 8998-711
Email: [email protected]

Admission holder and manufacturer:
Madaus GmbH
51101 Cologne

This information information was last revised 10/2010.

Source: Information of the leaflet
Status: 02/2016